TMBIM4 and Alzheimer disease: Importantly, two S1R ligands, such as Blarcamesine and Pridopidine, are in advanced clinical phases for the treatment of AD and Huntington’s Disease (HD), respectively, and their use in related pathologies is also under investigation [26,27,28].